Virtual key opinion leader discussion on the potential role of lacutamab

February 9, 2021 8:00 AM EST

The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:

  • Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator of Innate’s Phase 2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis fungoides and Sézary syndrome; and
  • Olivier Hermine, M.D., Professor of Hematology at the University of Paris Descartes and Director, Division of Adult Hematology at Hôpital Universitaire Necker Enfants Malades, Member of the Académie des Sciences, Member of the Lymphoma Study Association (LYSA), France

Presenters will provide an overview of the treatment landscape and prevalence of the lacutamab target, KIR3DL2, across subtypes of T-cell lymphoma. They will also highlight the potential impact of lacutamab in current and upcoming clinical programs in cutaneous and peripheral T-cell lymphomas.
 

The live webcast of the event will be available at the following link:

https://edge.media-server.com/mmc/p/yztsebvs


A telephone number will also be made available. Participants may register in advance of the event at http://emea.directeventreg.com/registration/2284358. Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.

A replay of the webcast will be archived on Innate’s website for 90 days following the event.

Supporting Materials